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-Catenin is a multifunctional molecule that is activated by signaling through WNT receptors. -Catenin
can also enhance the transcriptional activity of some steroid hormone receptors such as the androgen receptor
and retinoic acid receptor . Androgens can affect nuclear translocation of -catenin and influence its
subcellular distribution. Using mammalian two-hybrid binding assays, analysis of reporter gene transcription,
and coimmunoprecipitation, we now show that -catenin binds to the androgen receptor ligand-binding
domain (LBD) and modulates the transcriptional effects of TIF2 and the androgen receptor N-terminal domain
(NTD). In functional assays, -catenin bound to androgen receptor only in the presence of ligand agonists, not
antagonists. -Catenin binding to the androgen receptor LBD was independent of and cooperative with the
androgen receptor NTD and the p160 coactivator TIF2, both of which bind to the activation function 2 (AF-2)
region of the androgen receptor. Different mutations of androgen receptor helix 3 amino acids disrupted
binding of androgen receptor NTD and -catenin. -Catenin, androgen receptor NTD, and TIF2 binding to the
androgen receptor LBD were affected similarly by a subset of helix 12 mutations, but disruption of two sites
on helix 12 affected only binding of -catenin and not of TIF2 or the androgen receptor NTD. Mutational
disruption of each of five LXXLL peptide motifs in the -catenin armadillo repeats did not disrupt either
binding to androgen receptor or transcriptional coactivation. ICAT, an inhibitor of T-cell factor 4 (TCF-4), and
E-cadherin binding to -catenin also blocked binding of the androgen receptor LBD. We also demonstrated
cross talk between the WNT and androgen receptor signaling pathways because excess androgen receptor could
interfere with WNT signaling and excess TCF-4 inhibited the interaction of -catenin and androgen receptor.
Taken together, the data show that -catenin can bind to the androgen receptor LBD and modulate the effects
of the androgen receptor NTD and TIF2 on transcription.
Prostate cancer is an androgen-dependent malignancy that
usually undergoes clinical remission in response to hormone
deprivation but eventually relapses after cancer cells develop
the ability to grow in the presence of very low levels of andro-
gen or in response to adrenal steroids (25, 26). Prostate cancer
cells can develop resistance to hormone deprivation by aug-
menting signaling pathways activated by the androgen receptor
(AR). For example, a substantial fraction of prostate cancers
amplify the AR gene after treatment with hormone ablation
(27, 33, 53). Hormone deprivation and exposure to antiandro-
gens can also lead to selection for AR gene mutations that alter
response to antiandrogens and broaden the spectrum of ligand
agonists (4, 8, 10, 30, 36, 45, 47, 48, 50, 58, 59).
Androgen receptor activity can also undergo pathological
modulation in androgen insensitivity syndromes by disruption
of androgen receptor interaction with coactivator proteins that
mediate amplification of the androgen receptor transcription
signal or by mutations in the coactivator proteins themselves
(2, 39). In prostate cancer, mutations in the COOH-terminal
region of the androgen receptor can affect the binding of p160
coactivator molecules (18). Hormone-resistant prostate cancer
cells may also overexpress coactivators important for androgen
receptor signaling (17). Activating mutations in -catenin, a
multifunctional molecule responsible for transcriptional acti-
vation in WNT signaling, are found in 5% of prostate cancers
(3, 9, 34, 56). The potential significance of this finding was
underscored by the finding that -catenin interacts with the
androgen receptor to enhance androgen receptor transcrip-
tional activation and liberalize ligand specificity (52).
-Catenin armadillo repeats, particularly repeat six, were
shown to bind androgen receptor in a yeast two-hybrid inter-
action (62). Moreover, androgen caused nuclear localization of
-catenin and enhanced -catenin-mediated transcription (35,
38). In this report, we show that -catenin binds to the AF-2
region of the androgen receptor. Furthermore, binding is com-
plementary, not competitive, with both the androgen receptor
N-terminal domain (NTD) and the p160 coactivator TIF2 and
results in amplified transcriptional signals.
MATERIALS AND METHODS
Plasmids and plasmid construction. pGALD-H encodes the DNA binding
domain of the Saccharomyces cerevisiae GAL4 protein (amino acid residues 1 to
147) and the androgen receptor (amino acid residues 624 to 919) (we renamed
it GAL4/AR ligand-binding domain [LBD]), and pNLVP-hAR encodes the
transcriptional activation domain of the herpes simplex virus VP16 protein (res-
idues 411 to 456) and the full-length androgen receptor (we renamed it VP16/
* Corresponding author. Mailing address: Department of Oncology,
Lombardi Cancer Center, Georgetown University School of Medicine,
3800 Reservoir Rd. NW, Washington, DC 20007-2197. Phone: (202)
687-2207. Fax: (202) 784-1229. E-mail: gelmanne@georgetown.edu.
1674
AR) (28). VP16/AR1-660 and its deletion mutants (9-28, 179-199, 394-405,
429-439, and 339-499) code for the herpes simplex virus VP16 protein trans-
activation domain expressed as a fusion protein with the wild-type or deletion
mutated androgen receptor NH2-terminal and DNA binding domain (DBD;
residues 1 to 660) (20). GAL4/AR LBD-K720A and GAL4/AR LBD-V716R
have been described (19). All other individual point mutations in GAL4/AR
LBD were made with the Quick Change site-directed mutagenesis kit (Strat-
agene, La Jolla, Calif.). Mutations were confirmed by nucleotide sequencing.
pCMVhAR, pCMVhAR14-150, pCMVhAR142-337, and pCMVhAR339-
499 are expression vectors for wild-type full-length androgen receptor or andro-
gen receptor deletion mutants. pCMVhAR-(507-919) and pCMVhAR-(507-
919)-V716R encode the human androgen receptor DNA and ligand binding
domains without and with a single mutation in helix 3 of the androgen receptor
LBD, respectively. pCMVhAR-(1-503) encodes the N terminus of the androgen
receptor (43). Individual mutations in pCMVhAR-(507-919) were made with the
Quick Change site-directed mutagenesis kit as described above. The primers
were the same as listed above.
pcDNA3HA-AR-LBD has been described before (19) and was used for in
vitro translation of wild-type androgen receptor LBD peptides. -Catenin and its
individual LXXLL3AXXAA mutants were cloned in the pcDNA3.1 vector.
The mammalian two-hybrid system was used to assay in vivo protein-protein
interactions. Because preliminary experiments indicated that VP16 and GAL4
fusions with the C terminus of -catenin interfered with binding activity, we
made constructs in which the fusion partner was added to the N terminus of
-catenin. To construct VP16/-catenin, full-length -catenin was amplified by
PCR from pcDNA--catenin-Flag and cloned into the pCMX-VP16 vector with
5-GAGCTCGGATCCAGCCCGATCGGTACCT-3 and 5-ACTAGTGGAT
CCTTAGGCGTAGTCGGGGA-3 as the forward and reverse primers, respec-
tively. The primers have BamHI sites at both ends, and -catenin was cloned into
pCMX-VP16 at the BamHI site. The orientation and reading frame of the
resultant vector were confirmed by sequencing. To generate GAL4/-catenin
and Gal4/ARM--catenin expression vectors, full-length protein and the arma-
dillo repeat region of -catenin were amplified by PCR with 5-GAGCTCGGA
TCCACGCCCGATCGGTACCT 3 and 5-ACTAGTGGATCCTTAGGCG
TAGTCGGGGA-3 for full-length -catenin and 5-ATCCCGGGAAACTAT
CAAGATGATGCAGAA-3 and 5-ATGGATCCTTGTGGCTTGTCCTCAG
ACATT-3 for the armadillo repeat region. Both full-length -catenin and the
ARM region of -catenin were cloned downstream of the GAL4 DNA binding
sequences of the pCMX-GAL4 vector with the BamHI sites for full-length
-catenin and SmaI and BamHI sites for the armadillo repeat region. pCMX-
VP16 and -GAL4 vectors were kindly provided by Ronald Evans.
K435A mutations in pcDNA--catenin and VP16/-catenin were made with
the Quick Change site-directed mutagenesis kit as described above. pCS2/
S33A-VP16, which was renamed VP16/-catenin(S33A), pCS2/N-VP16,
which was renamed VP16/-catenin(15-552), and pCS2/S33AC-VP16,
which was renamedVP16/-catenin(576-781) (S33A), were kindly provided by
Andreas Hecht (21). In these constructs, -catenin S33A carries four alanine
substitutions in the glycogen synthase kinase 3 recognition site. pGEX-KT--
catenin, pGEX-KT--catenin(1-257), and pGEX-KT--catenin(418-781) encode
glutathione S-transferase (GST) fusion proteins of full-length, N-terminal, and
C-terminal -catenin. These vectors were kindly provided by David L Rimm,
Yale University, New Haven, Conn. (40).
TIF2, TIF2.5, and TIF2m1,2,3 have been described (54). pFR-LUC, pM,
pVP16, pSG5 and pBSK vectors were from Stratagene (La Jolla, Calif.). The
Renilla null luciferase reporter was from Promega (Madison, Wis.). MMTV-luc
has been described before (52). pcDNA3.1() was from Invitrogen (Carlsbad,
Calif.). TCF4 plasmid and OT/OF reporter vectors were provided by Bert Vo-
gelstein, Johns Hopkins Oncology Center, Baltimore, Md. pSVLGR encoding
rat glucocorticoid receptor (GR) was kindly provided by Stoney Simons (Na-
tional Institutes of Health, Bethesda, Md.). ICAT was kindly provided by T.
Nakamura, Institute of Molecular and Cellular Biosciences, University of Tokyo,
Tokyo, Japan.
Cell culture and transfection. CV-1 cells were routinely maintained in modi-
fied Iscove’s minimal essential medium supplemented with 5% fetal bovine
serum. Twenty-four hours before transfection, cells were plated in 24-well mi-
crotiter plates (Falcon) at a cell density of 4  104 cells per well. Transfection was
performed with Lipofectamine Plus reagent (Life Technologies, Inc.) with 10 ng
of receptor-containing plasmid, 100 ng of reporter, 10 ng of Renilla null lucif-
erase, and the indicated amounts of coregulators (TIF2, -catenin, or androgen
receptor N-terminal domain [NTD]). Unless otherwise stated in the figure leg-
ends, transfection was done with the total transfected DNA brought up to 300
ng/well with pBSK DNA.
In experiments with various amounts of coregulator cDNA plasmids, equimo-
lar amounts of the same plasmid vector were cotransfected to control for artifacts
of the vector DNA. The presence or absence of plasmid vector DNA added to
equalize the total DNA added to the culture had no effect on binding or tran-
scription assay. After incubation for 16 h, the cells were washed, and phenol
red-free medium supplemented with 5% dextran charcoal-stripped fetal calf
serum (CSS) containing hormones as indicated in the figure legends, or vehicle
was added. The final concentration of vehicle ethanol was 0.1%. Hydroxyflut-
amide was a gift from Rudolph Neri, Schering Corporation. RU-486 was ob-
tained from Sigma Chemical Co. After a further 24 h, cells were lysed in 1
passive lysis buffer (100 l/well; Promega), and 30 l of the cell lysates was used
to assay for luciferase activity with the dual-luciferase assay system from Pro-
mega (Madison, Wis.) according to the supplier. The data were then normalized
for the cotransfected Renilla activity. All samples were in triplicate, and each
experiment described was repeated at least two times.
To determine the effects of -catenin on TCF-dependent transactivation,
CV-1 cells were plated in 24-well plates and cotransfected as described above
with 10 ng of a TCF4 expression plasmid, 100 ng of the reporter plasmid OT
(containing three TCF binding sites upstream of the firefly luciferase cDNA),
and the indicated amount of -catenin or VP16/-catenin or their respective
mutants, with or without increasing amounts of wild-type GAL4/AR LBD or
GAL4/AR LBD(V889M) and 10 ng of Renilla null luciferase. Transfections were
completed to 300 ng/well with pBSK DNA and performed in triplicate. Firefly
and Renilla luciferase activities were measured, and TCF reporter activity was
corrected for transfection efficiency by determining the ratio of firefly and Renilla
luciferase activities.
GST pulldown assays. In vitro interactions between the androgen receptor
LBD and -catenin were examined by the GST pulldown assay. GST, GST–-
catenin, GST–-catenin(amino acids 1 to 257), and GST–-catenin(418 to 781)
fusion proteins were expressed in the CAG456 strain of Escherichia coli.
CAG456 is a derivative of a protease-deficient line and was used to minimize
degradation of the fusion protein products. GST fusion proteins were purified on
glutathione-Sepharose beads (Amersham Pharmacia Biotech, Arlington
Heights, Ill.). Androgen receptor LBD was translated in vitro with the TNT
coupled transcription-translation system (Promega Corp., Madison, Wis.) in the
presence of [35S]methionine. In the GST pulldown reactions, the translated
proteins were incubated for 30 min at room temperature in the presence or
absence of R1881 (106 M) before the addition of fusion proteins. The reactions
were incubated for 2 h at room temperature in NETN buffer (100 mM NaCl, 1
mM EDTA, 20 mM Tris-HCl, pH 8.0, and 0.5% Nonidet P-40), and the same
amounts of ligand as above with occasional mixing. The beads were then washed
five times with NETN buffer, and the bound 35S-labeled receptor was analyzed by
sodium dodecyl sulfate (SDS) gel electrophoresis, followed by autoradiography.
Immunoprecipitation and Western blotting. Antibodies were obtained as fol-
lows. TIF2 antibody was from Transduction Laboratories. Antibody to GRIP-1
(M-343) was a rabbit polyclonal antibody to amino acids 787 to 1129 of murine
GRIP-1 from Santa Cruz Biotechnology. Antibody M-343 reacts with GRIP-1 of
mouse, rat, and human origin by Western blotting. Anti-androgen receptor
antibody (PG-21) was from Upstate Biotechnology. Androgen receptor (441)
antibody was from Santa Cruz Biotechnology. Anti--catenin antibody was from
Transduction Laboratories. GAL4 DBD (RK5C1) antibody was from Santa
Cruz. Green fluorescent protein (GFP) antibody was from Clontech. -Actin
antibody was from Sigma.
For detection of the expression of GAL4/AR LBD mutants, COS-7 cells (1.5
 106) were plated overnight in 100-mm2 dishes. Cells were transiently cotrans-
fected with 3 g each of wild-type GAL4/AR LBD or different mutants, together
with 3 g of GFP vector with a Lipofectamine method according to the manu-
facturer’s protocol. For detection of the expression of -catenin and LXXLL
mutants, SKBR3 cells (2  106) were plated overnight in 100-mm2 dishes. Cells
were transiently transfected with 3 g each of -catenin and LXXLL mutants
together with GFP vector. Forty-eight hours after transfection, cells were col-
lected, washed with ice-cold phosphate-buffered saline (PBS), and lysed in lysis
buffer (20 mM Tris-HCl, pH 7.4, 120 mM NaCl, 1 mM EDTA, 0.5% Triton
X-100, 1 mM Na3VO4, supplemented with protease inhibitor mixture [Roche
Molecular Biochemicals]). The lysates were cleared by centrifugation (14,000 
g, 10 min at 4°C).
The total protein concentration of the extracts was measured with the DC
protein assay (Bio-Rad, Hercules, Calif.); 30 g of protein was loaded into a
precast 4 to 20% Tris-glycine gel (Invitrogen), followed by electrophoresis, and
subsequently transferred onto a nitrocellulose membrane (Bio-Rad). The mem-
branes were blocked overnight at 4°C with 5% milk in PBST (PBS containing
0.1% Tween 20). The membranes were washed three times for 10 min each with
PBST, followed by incubation at room temperature with a primary antibody in
PBST containing 1% milk. Antibodies for Western blot detection were the Gal4
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DBD antibody (1:500), -catenin antibody (1:2,000), anti-GFP antibody
(1:5,000), -actin antibody (1:5,000), or antibody to -tubulin (1:1,000). After an
hour of incubation, the membranes were washed three times for 10 min each with
PBST, followed by a secondary anti-mouse (GAL4, -catenin, -actin, and -tu-
bulin) or anti-rabbit (GFP) immunoglobulin-horseradish peroxidase antibody
(1:5,000) incubation for another hour at room temperature. Signal detection was
performed with Supersignal West Pico chemiluminescent substrate (Pierce).
Coimmunoprecipitation was done with transfected COS-7 cells (1.5  106)
plated overnight in 100-mm2 dishes. Cells were transiently cotransfected with 5
g each of androgen receptor, -catenin, and TIF2 vectors with a Lipofectamine
method. In some cases, COS-7 cells were transfected with -catenin together
with or without androgen receptor and/or TIF2. Sixteen hours after transfection,
cells were treated with 10 nM R1881 or ethanol. Twenty-four hours later, cells
were chilled on ice, washed with PBS, and lysed in lysis buffer. For the coimmu-
noprecipitation assay, 30 l/sample of 50% slurry protein A/G agarose beads
(Oncogene) was rinsed with PBS and incubated with 4 g of either anti-androgen
receptor antibody (PG-21) or anti-GRIP-1 antibody in 0.5 ml of lysis buffer at
4°C for 1 h. The beads were washed three times with ice-cold lysis buffer and then
incubated with 500 g of cell lysates at 4°C overnight. The beads were washed
five times with 1 ml of ice-cold lysis buffer. The immune complexes were col-
lected by adding 30 l of 2 SDS sample buffer. Samples were separated by
electrophoresis with 4 to 20% Tris-glycine gels and transferred to nitrocellulose.
Western blot detection was done as described above. Antibodies for Western
blot detection were anti-androgen receptor antibody 411 (1:500), -catenin an-
tibody (1:2,000), and TIF2 antibody (1:250).
Radioligand binding assay. Androgen receptor binding was determined in
COS-1 cells with a whole-cell binding assay (63). COS-1 cells were seeded into
24-well plates at a cell density of 6  104 cells/well in phenol red-free medium
containing 5% CSS. Forty-eight hours later, cells were transfected with 100
ng/well of wild-type GAL4/AR LBD or various point mutants together with 400
ng/well of pBSK with the Lipofectamine method. Sixteen hours after transfec-
tion, cells were cultured in fresh phenol red-free medium containing 5% CSS and
maintained for 24 h. Then cells were cultured in phenol red-free, serum-free
medium containing increasing concentrations (0.15625 to 5 nM) of [3H]R1881
(methyltrienolone, 83.5 Ci/mmol; Perkin Elmer Life Sciences) in the absence or
presence of a 200-fold molar excess of unlabeled R1881 (each with 0.14%
ethanol) for 90 min at 37°C. The binding was terminated by the addition of 1 ml
of ice-cold PBS. Cells were washed three times with ice-cold PBS, each for 3 min,
and cells were collected in 0.1 N NaOH and 1% Triton X-100 (0.1 ml/well) for
scintillation counting. The specific binding was calculated by subtracting the
nonspecific binding (200-fold R1881) from the total [3H]R1881 binding. The
binding capacity and affinity were determined by Scatchard plot analysis.
RESULTS
Androgen receptor LBD is necessary and sufficient for an-
drogen receptor/-catenin interaction. To clarify the role of
-catenin in mediating ligand-dependent transcription, we uti-
lized constructs containing the androgen receptor DBD and
LBD and a fusion protein of herpes simplex virus VP16 and
-catenin. The VP16/-catenin fusion protein can mediate
R1881-dependent transcription initiated by binding the andro-
gen receptor LBD to the androgen-responsive murine mammary
tumor virus (MMTV) long terminal repeat (LTR) promoter
(Fig. 1A). -Catenin alone increased androgen-dependent
transcriptional activity three- to fivefold, as we had previously
reported (Fig. 1B) (52). Because of the magnitude of the effect,
VP16/-catenin was used in subsequent transfection experi-
ments to study the androgen receptor/-catenin interaction.
To address more directly the interaction of the androgen
receptor LBD with -catenin, the VP16/-catenin fusion con-
struct was then used to mediate a mammalian two-hybrid in-
teraction with a GAL4/AR LBD fusion protein. As shown
earlier, expression of GAL4/AR LBD shows no induction of
transcriptional activity, indicating the absence of AF-2 activity.
However, when cells were cotransfected with VP16/-catenin,
the agonist R1881 induced GAL4-dependent transcription.
Both binding and transcriptional activity were ligand depen-
dent and proportional to the amount of VP16/-catenin plas-
mid added to the culture (Fig. 1C). That the exogenous ex-
pression of VP16/-catenin can rescue the agonist-dependent
AF-2 activity in the androgen receptor LBD complements our
previous findings that -catenin can enhance androgen recep-
tor-dependent transcription (52). This suggests a model in
which binding of a ligand agonist to the androgen receptor
LBD changes its conformation to form a surface correspond-
ing to the AF-2 domain, which in turn accommodates coacti-
vator binding (31, 42). Only about three- to fourfold induction
of luciferase activity was observed with the reciprocal chimeras
GAL4/-catenin and VP16/AR-LBD, suggesting a preferential
orientation for fusion protein interaction (data not shown).
Binding of -catenin was dependent on agonist-mediated
folding of the androgen receptor LBD around a ligand, since
antiandrogens such as hydroxyflutamide and cyproterone ace-
tate were unable to mediate binding, as was true for the anti-
progestin RU-486, which can also act as an antiandrogen (Fig.
1D) (51). In addition, excess antagonists were able to compete
with agonist occupancy of the receptor and disrupt the binding
of VP16/-catenin to the GAL4/AR LBD. Androgen receptor
binding of -catenin was mediated by physiologic concentra-
tions of androgen and increased at a slower rate for
R1881concentrations above 1 nM (Fig. 1E).
To ask if the N terminus of the androgen receptor is also
involved in the interaction with -catenin, we carried out the
mammalian two-hybrid assay with GAL4/-catenin and VP16/
AR(1-660) or deletion mutants (9-28, 179-199, 394-405,
429-439, and 339-499). The results showed that there was
no detectable induction of the reporter with any of the AR(1-
660) constructs compared with the VP16 control, suggesting
that the N terminus of the androgen receptor, including the
DNA binding domain of the androgen receptor, is not needed
for the interaction with -catenin (data not shown).
Interaction of androgen receptor LBD with -catenin and
androgen receptor NTD. The androgen receptor NTD binds to
the androgen receptor AF-2 region in the LBD via hydropho-
bic domains (19, 20). In the presence of ligand, full-length
androgen receptor was able to mediate the two-hybrid inter-
action with GAL4/AR LBD and initiate GAL4-dependent
transcription (Fig. 2A). Full-length androgen receptor was
more active than VP16/-catenin in this assay and was able to
synergize with VP16/-catenin to activate a very high level of
transcription. Androgen receptor mutants AR14-150 and
AR339-499 had reduced interaction with GAL4/AR LBD, to
levels 9% and 31% of that of the wild-type androgen receptor,
respectively. These two mutants had lost either the 23FQNLF27
or the 433WHTLF437 sequences that are required for interac-
tion of the androgen receptor LBD and NTD (20).
In the presence of VP16/-catenin, GAL4-dependent tran-
scription was still lower in the presence of these two deletion
mutants than in that of the wild-type androgen receptor. How-
ever, there was a mild interaction of the androgen receptor
deletion mutants and VP16/-catenin that was proportional to
the activities seen in the presence of VP16 alone, suggesting
that the domains responsible for N/C interaction of the andro-
gen receptor are required for the efficient interaction of an-
drogen receptor and VP16/-catenin. Deletion of the AF-1
function in AR142-337 caused almost total loss of GAL4-
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dependent transcription in response to R1881. Even though
AR142-337 could still interact efficiently with the androgen
receptor LBD (19), it could not activate the AF-2 function of
the GAL4/AR LBD chimera. Indeed, cotransfection of
AR142-337 with VP16/-catenin produced the same level of
GAL4-dependent transcription as with VP16/-catenin alone.
We next asked if the androgen receptor NTD was necessary
and sufficient for the synergistic effects with VP16/-catenin.
FIG. 1. Agonist-dependent interaction of -catenin with androgen receptor LBD. (A) VP16/-catenin enhances androgen receptor LBD-
mediated transactivation in CV-1 cells. Transient transfection of CV-1 cells was done with 10 ng of AR(507-919), 100 ng of MMTV-LUC, 10 ng
of Renilla null luciferase reporter, and increasing amounts of VP16/-catenin (0 to 200 ng/well) adjusted with VP16 expression vector to produce
equimolar amounts of VP16 vectors. The total amount of DNA in each well was brought to 320 ng with pBSK. (B) Similar experiment with
-catenin instead of VP16/-catenin. EtOH, ethanol. (C) The androgen receptor LBD interacts with -catenin in a dose-dependent manner.
Mammalian two-hybrid assay in CV-1 cells with 100 ng of the GAL4-responsive reporter plasmid pFR-LUC, 10 ng of GAL4/AR LBD, and
increasing amounts of VP16/-catenin. Empty VP16 expression vector was used to maintain equimolar concentrations across all cultures. (D) The
interaction of the androgen receptor LBD and -catenin is agonist dependent, and antagonists can block the interaction. CV-1 cells were
cotransfected with 10 ng of GAL4/AR LBD, 100 ng of pFR-LUC, 10 ng of Renilla null luciferase reporters, and 50 ng of VP16/-catenin as
described above. Vehicle, R1881, and antihormones were added as described in Materials and Methods. CPA, cyproterone acetate. (E) Androgen
receptor LBD interaction with -catenin is proportional to the concentration of R1881. CV-1 cells were cotransfected with 10 ng of GAL4/AR LBD, 100
ng of pFR-LUC, 10 ng of Renillla luciferase expression plasmid, and 50 ng of VP16/-catenin and treated with increasing amounts of R1881.
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AR(1-503) was cotransfected with the GAL4/AR LBD to-
gether with or without VP16/-catenin. As expected, AR(1-
503) mediated GAL4-dependent transcription (Fig. 2B).
Moreover, cotransfection of AR(1-503) and VP16/-catenin
induced a synergistic effect on reporter expression. Since there
was no direct interaction between AR(1-503) and VP16/-
catenin in the mammalian two-hybrid assay, we conclude that
AR(1-503) and VP16/-catenin might be able to bind to the
androgen receptor LBD independently, resulting in a synergis-
tic enhancement of transcription. As expected, the androgen
receptor LBD alone had a dominant negative effect on the
binding of GAL4/AR LBD and VP16/-catenin, consistent
with the interpretation that the androgen receptor LBD con-
tained the -catenin binding site (Fig. 2B, right panel).
We examined the relationship of the androgen receptor
NTD and -catenin binding to the androgen receptor LBD by
assaying their interaction with two mutants of the androgen
receptor LBD that contained single amino acid alterations in
helix 3. GAL4/AR LBD (V716R) is able to bind ligand but
does not interact with the androgen receptor NTD or the p160
coactivator TIF2 (19). We confirmed that this mutant had no
interaction with the androgen receptor NTD but was still able
to interact with VP16/-catenin (Fig. 2C). In contrast,
GAL4/AR LBD (K720A) reduced binding to the androgen
receptor NTD by 50%, but abrogated binding to VP16/-cate-
nin. Androgen receptor LBDs with either V716R or K720A
mutations are capable of agonistic binding with dihydrotestos-
terone that may have been enhanced by our use of R1881 (19).
VP16/-catenin and the androgen receptor NTD acted inde-
pendently in the presence of the V716R and K720A mutant
constructs, suggesting that the synergistic effects of -catenin
and the androgen receptor NTD were mediated by indepen-
dent binding of each to the androgen receptor LBD (Fig. 2C,
right side).
Interaction of androgen receptor LBD with -catenin and
TIF2. Binding studies with the helix 3 point mutants demon-
strated that there were differences between -catenin and an-
drogen receptor NTD binding to the androgen receptor LBD,
consistent with our finding that the two interacted synergisti-
cally with the androgen receptor LBD. Since the androgen
receptor NTD and the p160 coactivator TIF2 bind to similar
regions of the androgen receptor LBD, we examined the in-
teraction of -catenin and the androgen receptor LBD in the
presence of TIF2. We found that TIF2 was a potent activator
of GAL4-dependent transcription, and therefore the mamma-
lian two-hybrid experiments were done with TIF2 instead of a
VP16/TIF2 hybrid (Fig. 3A). The mutant TIF2.5 has deletions
of the entire N- and C-terminal regions of TIF2 to leave only
the nuclear receptor-interacting domain (amino acids 624 to
869) and is unable to mediate transcription. TIF2.5 was inac-
tive in the mammalian two-hybrid assay, as was TIF2m123,
which has all three NR boxes mutated (LXXLL3LXXAA) to
eliminate binding to nuclear receptors (Fig. 3) (54).
TIF2.5 had a dominant negative effect on the interaction of
TIF2 and the androgen receptor LBD on GAL4-mediated
transcription, consistent with the interpretation that TIF2.5
bound to the androgen receptor but was unable to mediate
formation of the transcriptional complex (Fig. 3, far right).
However, neither TIF2.5 nor TIF2m1,2,3 blocked the effect of
VP16/-catenin. This result suggests that -catenin bound to
the androgen receptor independently of TIF2 and was not
affected by the dominant negative TIF2.5 mutant.
The interaction of -catenin with TIF2 and the androgen
receptor NTD in affecting androgen receptor-dependent tran-
scription is shown in Fig. 3B. In contrast to previous findings
that -catenin and SRC-1 had similar stimulatory effects on
androgen receptor-dependent transcription, TIF2 was more
potent at stimulating the MMTV-driven reporter construct.
-Catenin modulated TIF2 activation of androgen receptor-
FIG. 2. Synergistic effect of VP16/-catenin and androgen receptor
NTD on androgen receptor AF-2. (A) CV-1 cells were cotransfected
with 10 ng of GAL4/AR LBD, 100 ng of pFR-LUC, 50 ng of pCM
VhAR or the indicated deletion mutants together with 50 ng of VP16/
-catenin or 30 ng of VP16 expression vector. (B) CV-1 cells were
cotransfected as described for panel A except that pCMVhAR1-503 or
pCMVhAR507-919 was used. (C) VP16/-catenin and the androgen
receptor NTD require different amino acids for binding to the andro-
gen receptor LBD. CV-1 cells were transfected as described for panel
B except that both wild-type and mutant GAL4/AR LBD (K720A and
V716R) were used.
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dependent transcription and enhanced the effect of the andro-
gen receptor NTD. However, the effects of -catenin on an-
drogen receptor-dependent transcription in the presence of
TIF2, the androgen receptor NTD, or both were small com-
pared to the binding interactions that were assayed by GAL4-
dependent transcription.
Androgen receptor, -catenin, and TIF2 form a physical
complex. To demonstrate that androgen receptor, TIF2, and
-catenin formed a physical complex, we transfected COS-7
cells with expression plasmids for the three proteins and per-
formed coimmunoprecipitation experiments. Figure 4 shows
the results of these immunoprecipitation/Western blot exper-
iments. Antibody to androgen receptor was able to immuno-
precipitate TIF2 in the absence of ligand, but in a manner that
was enhanced by the presence of R1881 (Fig. 4A). This is in
agreement with reports that p160 coactivators such as TIF2 can
interact with the conserved glutamine-rich region of the an-
drogen receptor NTD in a ligand-independent manner (5).
Antibody to androgen receptor also coimmunoprecipitated
-catenin in an androgen-dependent association, as we had
previously published (52) (Fig. 4B).
GRIP-1 antibody cross-reacts with TIF2 and pulls down
-catenin. Because of the abundance of TIF2 in COS-7 cells,
we performed the experiment in the presence and absence of
exogenous TIF2 expression vector to demonstrate specificity.
The association of these two, presumably via binding to the
androgen receptor, was not hormone dependent (Fig. 4C). We
were also able to detect androgen receptor in the complex
precipitated by GRIP-1 antibody. Similar to the association of
GRIP-1 and -catenin, this association was not androgen de-
pendent but was augmented by exogenous TIF2 expression
(Fig. 4D).
-Catenin binding to helix 12. The AF-2 domain of the
androgen receptor LBD is formed after a ligand agonist binds
to the LBD and helix 12 forms a surface with helices 3, 4, and
5 to which coactivator molecules and the androgen receptor
NTD bind (31, 41). We examined the effects of individual
amino acid alterations in helix 12 in order to develop a finger-
FIG. 3. (A) Combined effect of VP16/-catenin and TIF2 on androgen receptor AF-2. CV-1 cells were cotransfected with 10 ng of GAL4/AR
LBD, 100 ng of pFR-LUC, 50 ng of VP16/-catenin, or 30 ng of VP16 expression vector, 50 ng of pSG5-TIF2, TIF2.5, or TIF2m1,2,3, or an
equimolar amount of the pSG5 expression vector. (B) Combined effect of -catenin, TIF2, and the androgen receptor NTD on androgen
receptor-dependent transcription. CV-1 cells were cotransfected with 10 ng of pCMVhAR507-919, 100 ng of MMTV-LUC, 50 ng of -catenin, 10
ng of pSG5-TIF2, 10 ng of AR(1-503), or an equimolar amount of the pSG5 expression vector.
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print of helix 12 amino acids that affect androgen receptor
LBD binding and transcriptional activation when combined
with VP16/-catenin, TIF2, and the androgen receptor NTD.
Mutations in the androgen receptor C terminus were chosen
based on known changes that caused androgen insensitivity
syndromes (V889M, P892L, M895T, V903M, P904S, L907F,
and G909R), as referenced in the androgen receptor database
(http://ww2.mcgill.ca/androgendb/). Q902R is a mutation iden-
tified in prostate cancer (48). M894D is an androgen insensi-
tivity mutation (49). Other helix 12 amino acids were each
changed to alanine. The mutations were introduced into
GAL4/AR LBD plasmids for the mammalian two-hybrid assay
and into AR DBDLBD(507-919) for the transactivation as-
say with an MMTV LTR reporter construct.
The constructs were assayed for their ligand binding activity
to address concerns about the effect of reduced ligand binding
on the interaction of the androgen receptor LBD with binding
partners. The Kd of the wild-type androgen receptor construct
was 0.083 nM, in agreement with a previously reported result
with the same construct of 0.11 nM (19). Ligand binding of the
different helix 12 mutants as reflected by the Kd ranged from
0.08 nM to 0.739 nM. Because ligand-binding affinity varied
approximately 10-fold, binding and transcription studies with
these constructs were done in the presence of 100 nM R1881.
For each construct, we assayed either GAL4-dependent tran-
scription or androgen receptor-dependent transcription in the
presence of VP16/-catenin, TIF2, or the androgen receptor
NTD. Results of binding and transcription experiments are
shown in Table 1.
The locations of mutated amino acids are shown on the
contour drawing of the androgen receptor in Fig. 5. Mutations
at amino acids 891 and 892 abrogated all interactions of the
androgen receptor LBD with VP16/-catenin, TIF2, and the
androgen receptor NTD. Adjacent to those two amino acids,
FIG. 4. Immunoprecipitation/Western blotting of TIF2, androgen
receptor, and -catenin. (A) Immunoprecipitation (IP) with androgen
receptor antibody and Western blotting (WB) with antibody to TIF2.
The left panels show the input material. LNCaP cell extracts were
included as an additional standard. (B) Immunoprecipitation with an-
tibody to -catenin and Western blot with androgen receptor antibody.
(C) Immunoprecipitation with antibody to murine GRIP-1 fragment
and Western blot with -catenin. Note that the presence of exogenous
TIF2 enhances the signal generated with endogenous TIF2. (D) Same
as C but Western blot with androgen receptor antibody.
TABLE 1. Binding activity and transcriptional activity of helix 12 mutant androgen receptor constructsa
Mutation






VP16/-catenin TIF2 VP16/AR (1–660) VP16/-catenin TIF2 AR (1–503)
None 0.0832 2,630
V889M 0.222 1,779 0.14 	 0.18 15.76 	 0.43 2.94 	 0.36 2.09 	 0.96 43.03 	 4.96 9.24 	 1.56
F891A 0.739 1,201 0.2 	 0.10 0.05 	 0.23 0.06 	 0.07 0.01 	 0.10 0.04 	 0.04 0.24 	 0.09
P892L 0.333 762 0.03 	 0.02 0.05 	 0.10 0 	 0.05 0.17 	 0.06 0.26 	 0.05 0.45 	 0.16
E893A 0.0512 2,120 10.26 	 3.8 58.1 	 7.36 9.68 	 1.98 5.19 	 1.35 27.31 	 4.07 27.51 	 7.47
M894A 0.133 1,893 31.15 	 6.8 0.15 	 0.13 34.6 	 8.47 23.82 	 3.27 2.16 	 1.44 52.04 	 7.89
M894D 0.166 2,326 17.38 	 4.64 0.02 	 0.26 4.13 	 0.08 42.41 	 0.24 0.16 	 0.20 7.22 	 4.49
M895T 0.222 1,454 9.63 	 1.52 3.4 	 1.02 16.09 	 3.45 30.98 	 4.98 31.2 	 5.32 47.37 	 4.58
A896V 0.166 1,944 114 	 23.08 29.77 	 9.23 43.43 	 10.3 47.81 	 7.05 40.79 	 10.62 69.44 	 8.94
E897V 0.111 2,170 207.6 	 60.15 2.47 	 1.97 0.13 	 0.05 84.5 	 13.7 0.38 	 0.35 0.23 	 0.04
I898A 0.166 2,149 18.09 	 1.31 43.91 	 6.61 0.68 	 0.31 43.78 	 13.57 73.45 	 17.39 26.1 	 5.31
I899A 0.222 2,163 15.7 	 6.02 45.33 	 5.02 15.98 	 7.01 59.6 	 30.4 85.8 	 16.3 69.04 	 1.2
Q902R 0.0739 2,691 74.31 	 21.43 0.06 	 0.30 1.03 	 0.11 27.45 	 1.53 0.44 	 0.25 6.75 	 1.79
V903M 0.0832 2,146 85.76 	 29.0 26.04 	 11.92 34.71 	 5.37 66.99 	 13.58 27.67 	 4.56 64.64 	 11.04
P904S 0.665 3,014 0.87 	 0.37 1.64 	 1.14 8.06 	 0.73 6.4 	 0.75 14.54 	 0.50 46.44 	 2.69
K905A 0.111 1,838 65.67 	 25.25 46.27 	 7.87 45.61 	 9.68 66.8 	 4.77 1.02 	 0.14 13.61 	 2.13
L907F 0.222 2,420 13.61 	 7.21 40.32 	 11.63 19.89 	 4.4 22.54 	 5.80 47.07 	 6.49 52.67 	 10.18
G909R 0.333 2,266 59.29 	 9.41 17.24 	 0.56 17.38 	 1.04 31.02 	 4.41 17.7 	 2.12 48.08 	 8.73
a Two-hybrid interaction was determined with 10 ng of wild-type GAL4/AR LBD or the indicated point mutants and 50 ng of either VP16/-catenin, TIF2, or
VP16/AR(1–660), together with 100 ng of pFR-LUC and 10 ng of Renilla null luciferase reporters. Transactivation assay was determined by transfecting 10 ng of
wild-type pCMVhAR507-919 or the indicated mutants, 100 ng of MMTV-LUC, and 50 ng of VP16/-catenin, TIF2, or pCMVhAR1-503, together with 100 ng of
pFR-LUC and 10 ng of Renilla null luciferase reporters. Cells were treated with 100 nM R1881 in phenol red-free medium for 24 h and assayed for firefly and Renilla
luciferase activities as described in Materials and Methods. The induction by R1881 was determined for each mutant in the presence of individual factors, and the
induction of wild-type GAL4/AR LBD and pCMVhAR507-919 were set at 100%, The percent binding activity to GAL/AR LBD mutants or percent transcriptional
activity mediated by pCMVhAR507-919 mutants was then calculated as (induction of mutant  1)/(induction of wild type  1)  100. Negative values indicate that
the induction of the mutant by R1881 was less than 1 (the ethanol control value taken as 1).
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mutation of V889 and E893 reduced binding and activity but
more so for VP16/-catenin and the androgen receptor NTD
than for TIF2. M894 was also important for the interactions.
M894A reduced the interaction with TIF2 more than with
VP16/-catenin and the androgen receptor NTD. However,
M894D affected androgen receptor LBD interactions with
both TIF2 and the androgen receptor NTD. Note in Fig. 5 that
M894 is immediately adjacent to P892, a critical determinant
of androgen receptor interaction with TIF2, VP16/-catenin,
and the androgen receptor NTD. M895 is barely exposed to
the surface, lying beneath E893 and M894, and therefore was
not labeled in Fig. 5. The M895T mutation reduced binding
but preserved transcriptional activity in interactions with TIF2,
VP16/-catenin, and the androgen receptor NTD.
Other mutations were found to selectively affect interactions
with one or another of VP16/-catenin, TIF2, and the andro-
gen receptor NTD. For example, E897V disrupted the inter-
action with TIF2 and the androgen receptor NTD but pre-
served the interaction with VP16/-catenin. It is noteworthy
that mutation of both amino acids 897 and 902 preserved the
interaction with VP16/-catenin but abrogated the interactions
with TIF2 and the androgen receptor NTD. However, we
found no mutation that abrogated the interaction of the an-
drogen receptor LBD with VP16/-catenin but preserved the
FIG. 5. Space-filled model with Van der Waals radii of androgen receptor LBD viewed with CHIME according to the structure published by
Matias et al. (31). The surface of the molecule shown at the tip was rotated upward and to the left to show the progressive views, as shown by the
arrows. Amino acids mutated for the functional studies are indicated.
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interaction with TIF2 and the androgen receptor NTD, al-
though E893A approximated this phenotype. Lastly, P904S,
which appears on the model in Fig. 5 to be separated from the
critical region around amino acids 891 and 892, also had a
substantial effect on binding of TIF2, VP16/-catenin, and the
androgen receptor NTD and an effect on the transcriptional
interaction of the androgen receptor LBD with VP16/-cate-
nin and TIF2. The expression levels of all the helix 12 mutant
androgen receptor constructs were found to be similar by
Western blotting (data not shown). Therefore, differences in
activity were not due to differences in expression.
Analysis of androgen receptor-binding regions of -catenin.
We also examined regions of -catenin that were required for
binding to the androgen receptor. Yang has recently shown
that the armadillo repeats are required for yeast two-hybrid
interaction between the androgen receptor and -catenin (62).
-Catenin constructs comparing an S33A mutant full-length
expression vector with constructs that removed either the N- or
C-terminal armadillo repeats showed that either of the two
large deletions nearly abrogated binding (Fig. 6A and B) and
transactivation (Fig. 6C). The S33A mutant -catenin was used
as a positive control in these experiments because the 15-552
construct is deleted of the N-terminal phosphorylation sites
that target -catenin for degradation.
Mulholland also examined the physical interaction of andro-
gen receptor and -catenin by GST pulldown, showing that
androgen receptor-GST interacted most strongly with the
-catenin armadillo repeats (35). Because androgen receptor-
GST constructs often do not show ligand dependence (44), we
employed -catenin–GST constructs and showed that ligand-
dependent androgen receptor pulldown occurred with full-
length and C-terminal fragment of -catenin (that included
armadillo repeats 8 to 12) but to a lesser degree with the
N-terminal region that included armadillo repeats 1 to 3 (Fig.
FIG. 6. (A) Structural arrangement of VP16/-catenin constructs in this experiment, demonstrating the location of armadillo repeats. (B) CV-1
cells in a mammalian two-hybrid assay were cotransfected with 10 ng of GAL4/AR LBD, 100 ng of pFR-LUC, 10 ng of Renilla null luciferase
reporter, and 50 ng of VP16/-catenin(S33A), VP16/-cateninN, or VP16/-cateninC(S33A). (C) CV-1 cells in a transactivation assay were
cotransfected with 10 ng of pCMVhAR507-919, 100 ng of MMTV-LUC, 50 ng of VP16/-catenin(S33A), VP16/-cateninN, VP16/-
cateninC(S33A), or equimolar amounts of VP16 empty vector. (D) In vitro interaction of the androgen receptor LBD with -catenin. [35S]AR
LBD was synthesized in vitro and incubated in the presence or absence of 1 M R1881, with glutathione-Sepharose beads bound with
GST–-catenin, GST–-catenin(1-257), or GST–-catenin(418-781). Control beads contained GST alone. Beads were washed, and bound
35S-labeled proteins were eluted and analyzed by SDS-PAGE and autoradiography. The input lane contained 20% of the total radioactivity added
for each reaction.
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6D). The association of androgen receptor with GST–-cate-
nin and GST–-catenin(1-257) was ligand responsive. The as-
sociation of androgen receptor with GST–-catenin(418-781)
showed no ligand responsiveness. Therefore, there was demon-
strable physical association of androgen receptor and portions
of -catenin even though these associations were inert for
transcriptional activation. The binding of full-length GST–-
catenin to the androgen receptor that was enhanced by the
presence of R1881 is quite similar to the coimmunoprecipita-
tion of -catenin and the androgen receptor that occurred in
the absence of androgen but was enhanced by the presence of
androgen (52).
Nuclear receptor coactivators bind to the AF-2 region of
androgen receptor via peptide motifs called NR boxes with the
consensus sequence LXXLL. -Catenin contains five such do-
mains in armadillo repeats 1, 3, 7, 10, and 12. To determine the
role, if any, of these repeats, we mutated each individually to
AXXAA and then used the full-length -catenin construct in
binding (Fig. 7A) and transactivation (Fig. 7B) assays. Muta-
tion of the LXXLL motifs in armadillo repeats 1 and 3 actually
stimulated both binding to and transactivation of androgen
receptor, although the effect may have been due to a large
degree to overexpression of the LXXLL3 construct (Fig. 7C).
Mutations of the other three LXXLL domains had very little
effect on binding of VP16/-catenin to GAL4/AR LBD or on
the transcriptional interaction of -catenin with androgen re-
ceptor.
-Catenin has a common mode of binding to diverse mole-
cules such as E-cadherin and the adenomatous polyposis coli
(APC) protein. These proteins bind to a groove formed by the
armadillo repeats and are anchored to two lysine residues at
positions 312 and 435 (13). The inhibitor of -catenin and
T-cell factor (TCF) 4 (ICAT) protein interferes with TCF4/-
catenin interaction by binding to the same region of the -cate-
nin armadillo repeats that interacts with TCF4 (W. Weis, per-
sonal communication) (46). We found that ICAT expression
completely abrogated binding of -catenin to the androgen
receptor LBD in a mammalian two-hybrid assay and blocked
the -catenin-induced enhancement of androgen receptor
transcriptional activation (Fig. 8). However, ICAT had no ef-
fect on the interaction of TIF2 and the androgen receptor LBD
(Fig. 8, insets).
We also examined the degree of cross talk between TCF-
dependent and androgen-dependent transcription. Androgen
receptor interfered with the transcription from a TCF-respon-
sive promoter in a manner that was to some degree hormone
dependent. In the absence of -catenin, activation of the TCF-
responsive reporter was very low and not affected by the pres-
ence of androgen receptor (Fig. 9A) (35, 38). In contrast, the
glucocorticoid receptor did not influence the activation of a
TCF-responsive reporter by TCF-4 and -catenin (Fig. 9B)
(35). We also showed that the androgen receptor LBD was
able to interfere with TCF-dependent transcription. However,
when the AR(507-919)V889M mutant was titrated in the re-
porter assay, no effect on TCF-dependent transcription was
seen (Fig. 9C and D and Table 1).
Lastly, TCF-4 expression also interfered with -catenin (Fig.
9E) and VP16/-catenin (Fig. 9F) enhancement of androgen
receptor-dependent transcription from the MMTV LTR. We
also used the -catenin mutant construct K435A as a negative
control in these cross talk experiments. K435 is one of the
residues critical for the interaction between -catenin and mol-
ecules like TCF, E-cadherin, and APC (16, 57). We have found
that the -catenin K435A mutation preserves interaction with
the androgen receptor even though it diminishes interaction
with TCF-4 by more than 80% (L.-N. Song and E. P. Gelmann,
unpublished observations). Therefore, the -catenin K435A
expression vector blunted the inhibitory effect of TCF-4 on
androgen receptor-dependent transcription (Fig. 9E and F).
DISCUSSION
Our data show that -catenin binds to the androgen recep-
tor, activates transcription to some degree, and modulates the
effects of TIF2 and the androgen receptor NTD. Of interest is
the finding that the androgen receptor binding site for -cate-
nin is adjacent but not identical to the AF-2 binding sites for
FIG. 7. LXXLL motifs in armadillo repeats of -catenin are not
required for the interaction with androgen receptor LBD. (A) CV-1
cells in a mammalian two-hybrid assay were cotransfected with 10 ng of
GAL4/AR LBD, 100 ng of pFR-LUC, 100 ng of wild-type -catenin,
individual LXXLL3AXXAA mutants, or an equimolar amount of
pcDNA3.1 (B) CV-1 cells in a transactivation assay were cotransfected
as described for panel A except that pCMVhAR507-919 and MMTV-
LUC were used. (C) Western blot analysis of wild-type -catenin and
its mutants in SKBR3 cells, chosen for this analysis because they have
very low endogenous expression of -catenin.
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TIF2 and the androgen receptor NTD. Moreover, -catenin
binding to the androgen receptor is absolutely dependent on
the presence of a ligand agonist, suggesting that the confor-
mation induced by binding of a ligand agonist is required for
-catenin binding. p160 coactivator binding to nuclear recep-
tors occurs at a specific groove that is created by the juxtapo-
sition of helices 3, 4, 5, and 12 that is formed by swiveling of
helix 12 over the ligand binding pocket (11, 32, 37, 42, 61).
When a receptor antagonist is bound, helix 12 assumes a po-
sition unfavorable for coactivator binding. Mutational analysis
has confirmed that helices 3, 4, 5, and 12 are the sites of
activating factor 2 (AF-2) activity, which is important for p160
coactivator binding (42). Three-dimensional analysis of the
androgen receptor LBD has shown that the androgen receptor
has a similar structure and undergoes similar conformational
changes in response to ligand binding as was demonstrated for
other nuclear hormone receptors (31, 41).
-Catenin appears to complex with the androgen receptor in
proximity to the androgen receptor NTD or TIF2. -Catenin
binding depends on the integrity of K720, which also affects
TIF2 binding to some degree, while the androgen receptor
NTD and TIF2 require V716 (19). Both residues are in helix 3.
Moreover, -catenin depends on a subset of amino acids in
helix 12 that are required for the androgen receptor NTD and
TIF2 interactions. Two amino acids are required for androgen
receptor LBD interactions with the androgen receptor NTD
and TIF2 but have no effect on interactions with VP16/-
catenin. -Catenin enhanced the binding and activity of the
androgen receptor complex with TIF2 and the androgen re-
ceptor NTD. This implies but does not prove that -catenin
can bind to the androgen receptor at the same time that either
of these other proteins binds to the androgen receptor.
Importantly, the dominant negative TIF2.5 mutant, which
contains only the nuclear receptor interacting domain, com-
pletely abrogated TIF2 coactivation but had no effect on
-catenin interaction with the androgen receptor. The mech-
anism of -catenin’s interaction with these moieties is not yet
clear. It may be that -catenin acts to stabilize binding and
formation of a transcriptional complex. Alternatively, -cate-
nin may recruit additional transcriptional machinery to the
complex and thereby enhance the degree of transcriptional
activation. Other explanations include stabilization of hor-
mone binding and interference with putative binding of core-
pressors similar to those identified for the progesterone recep-
tor (22). Taken together, the data suggested that ligand-bound
androgen receptor forms a binding groove with helices 3, 4, 5,
and 12 that binds to the armadillo repeats of -catenin and
allows -catenin to bind in such a way that it can complement
the transcriptional activity of both TIF2 and the androgen
receptor NTD.
Interactions between the androgen receptor and WNT sig-
naling pathways have important implications for our under-
standing of prostate cancer. We had initially found that a small
fraction of prostate cancer specimens contain 5 dominant
activating mutations affecting the phosphorylation sites of
-catenin (9, 56). Since prostate cancers generally do not have
a high rate of APC mutations and have not been found to
harbor disruptions in WNT signaling components, the signifi-
cance of the -catenin mutations across the spectrum of pros-
tate cancers was unclear (60). Recent findings have now pro-
vided strong evidence for cross talk between the WNT and
androgen receptor signaling pathways.
Androgen can induce nuclear localization of -catenin, and
-catenin can enhance androgen receptor signaling (35, 38, 52,
62). However, whereas -catenin is a moderate activator of
androgen receptor activity, in reporter assays ligand-bound
androgen receptor decreased TCF-4 transcriptional activity,
presumably by competing for -catenin binding to TCF-4. Be-
cause -catenin has functions in the cytoplasm as well as the
nucleus, ligand binding of androgen receptor has the potential
to alter the intracellular distribution of -catenin and thereby
either affect cell surface signals from E-cadherin or exert subtle
effects on WNT signaling.
-Catenin also interacts with the retinoic acid receptor-. In
the right cellular milieu, retinoids can increase -catenin sta-
bility and localization to the cell surface (7). In other contexts,
-catenin can enhance transcriptional activation by retinoic
acid receptor  and can compete with TCF for binding to
-catenin (12). -Catenin does not interact with all nuclear
hormone receptors and, specifically, has failed to show inter-
action with the retinoid X receptor, peroxisome proliferator-
activated receptor, estrogen receptor, and glucocorticoid re-
ceptor (12, 35, 52).
Coactivator molecules contain a consensus peptide of the
FIG. 8. ICAT can block the functional and physical interaction of
androgen receptor LBD and -catenin. (A) CV-1 cells in a mammalian
two-hybrid assay were cotransfected with 10 ng of GAL4/AR LBD, 100
ng of pFR-LUC, and 50 ng of VP16/-catenin, together with increasing
amounts of ICAT (0 to 10 ng/well). Equimolar amounts of empty
vector were also included. As controls, triplicate cultures of CV-1 cells
were also cotransfected as described above except that 50 ng of TIF2
was added instead of -catenin (inset). (B) Transactivation assays. As
in panel A except that pCMVhAR507-919 and MMTV-LUC were
used in the transfection.
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motif LXXLL, where L is leucine and X is any amino acid, in
a region called the NR box, which binds to the groove in
steroid hormone receptors (15, 55). Many of these proteins
belong in the steroid receptor coactivator (SRC) family and
bind to the AF-2 region in the C terminus of ligand-bound
receptors such as the estrogen receptor. Other proteins, such
as CREB-binding protein, complex with the androgen receptor
near the DBD to participate in a multiprotein transcriptional
complex (1, 22, 29). Hormone-dependent binding of p160 co-
activators through the LXXLL motifs results in the activation
of histone acetyltransferase activity, which plays a role in chro-
matin remodeling to allow active transcription of DNA (6, 14).
Elimination of any one LXXLL motif in -catenin had no
inhibitory effect on the interaction with androgen receptor. In
fact, mutation of the two proximal LXXLL motifs stimulated
both binding and coactivation of androgen receptor. Even
FIG. 9. Cross talk between androgen receptor-dependent and TCF-dependent transcription. (A) CV-1 cells were cotransfected with increasing
amounts of pCMVhAR, 10 ng of TCF4, and 100 ng of OT-LUC, together with or without 100 ng of -catenin expression plasmid. Sixteen hours
after transfection, cells were cultured in phenol red-free medium and treated with 1 nM R1881. At 24 h after induction, cells were harvested and
assayed for firefly and Renilla luciferase activities as described in Materials and Methods. The average values were normalized for cotransfected
Renilla, and the error bars represented the standard deviation within a given experiment. (B) CV-1 cells were cotransfected with increasing
amounts of pSVLGR, 10 ng of TCF-4, 100 ng of OT-LUC, and 100 ng of -catenin. Cells were treated as in A but with 100 nM dexamethasone
instead of R1881. (C) TCF-4-dependent transcription from the OT reporter construct in the presence of the -catenin expression plasmid and
AR(507-919) in the presence or absence of R1881. (D) Same as in panel C except the AR(507-919) construct contained the V889M mutation that
disrupted the interaction with -catenin. (E) CV-1 cells were transfected with the MMTV-LUC reporter, AR(507-919), expression vector for
-catenin or -catenin(K435A), and increasing amounts of the expression vector for TCF-4. (F) The experiment was carried out as in panel E
except for the use of VP16/-catenin fusion constructs instead of -catenin.
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though we cannot exclude the possibility that more than one
LXXLL motif might be required for the interaction, we still
predict that these LXXLL motifs are not crucial for the inter-
action with androgen receptor because our ongoing studies
suggested that several residues outside armadillo repeats 1, 3,
7, 10, and 12 are required for the interaction (data not shown).
Furthermore, Yang has argued that LXXLL motifs 7, 10, and
12 are not likely to be exposed on the surface of -catenin and
are probably not available for binding (62). Moreover, he has
shown that the armadillo repeats, in particular repeat 6, are
essential for androgen receptor binding.
The -catenin armadillo repeats form a rigid contour of
-helices formed by the armadillo repeats. APC, TCF-4, and
ICAT bind to -catenin over a common region of the mole-
cule’s surface and anchor at two lysine residues called charge
buttons (23, 24; W. Weis, personal communication). Since
ICAT blocked androgen receptor binding to -catenin, we
propose that the AF-2 region of the androgen receptor can
form a similar surface to interact with -catenin even when it
is bound to the androgen receptor NTD or TIF2. Further
studies will be needed to elucidate the structural details of
androgen receptor binding to -catenin.
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